Dai­ichi Sankyo forges $12M pact for GPCR pain pro­gram with Hep­tares; In­cyte shares jump on lat­est takeover chat­ter

→ Hep­tares struck a $12 mil­lion deal to part­ner with Dai­ichi Sankyo on a new GPCR pain drug. The UK biotech gets $4 mil­lion up­front and $8 mil­lion in re­search sup­port along with an un­spec­i­fied set of mile­stones for the deal, in which the So­sei sub­sidiary will search for new drugs that can be de­vel­oped for pain. Said CEO Mal­colm Weir: “We are con­fi­dent that the unique struc­tur­al in­sights of the re­cep­tor that our tech­nolo­gies can de­liv­er com­bined with ex­per­tise on its role in pain from the Neu­ro­sciences team at Dai­ichi Sankyo will yield new, dif­fer­en­ti­at­ed mol­e­cules that can be ad­vanced in­to de­vel­op­ment.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.